BHVN Biohaven Pharmaceutical Holding Company Ltd.

+0.06  (+0%)
Previous Close 61.7
Open 62.27
Price To Book 28.2
Market Cap 2741865709
Shares 44,395,494
Volume 275,108
Short Ratio 4.29
Av. Daily Volume 664,859

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 trial enrolling.
Obsessive compulsive disorder (OCD)
NDA acceptance announced November 25, 2018. PDUFA date not supplied. Estimate July 26, 2019.
Amyotrophic lateral sclerosis (ALS)
Phase 3 top-line data due 4Q 2019.
Migraine - preventative
Phase 3 data presented at AAN May 2019.
Zydis ODT formulation of rimegepant
Phase 2 enrolment to be completed 4Q 2019. Futility analysis also due 4Q 2019.
Alzheimer’s disease
Phase 3 enrolment to be completed by the end of 2019.
Generalized anxiety disorder (GAD)
Phase 3 trial to be initiated 3Q 2019.
Multiple system atrophy (MSA)
Phase 2/3 top-line data due 4Q 2019.
Acute treatment of migraine
Phase 3 enrolment to be completed 1Q 2020.
Spinocerebellar Ataxia (SCA)

Latest News

  1. Biohaven Announces Expanded Safety And Preliminary Preventive Efficacy Data From Ongoing Long-Term Safety Study, And Presents Case Reports Of Using Rimegepant To Successfully Treat Breakthrough Migraine Attacks In Patients Taking Preventive CGRP-Targeting Monoclonal Antibodies
  2. Biohaven Advances Late Stage Clinical Programs And Novel Targets From Neuroinnovation Platforms
  3. Biohaven Pharmaceuticals Reports First Quarter 2019 Financial Results And Advancements In Neuroinnovation Platforms
  4. Biohaven Announces Late-Breaking Oral Presentation Of Rimegepant Zydis® ODT Phase 3 Results At American Academy Of Neurology (AAN) 2019 Annual Meeting And New Data Release At Investor Event
  5. Hedge Funds Have Never Been This Bullish On Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
  6. Analysts point to potential Biogen M&A options after Alzheimer's failure
  7. The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives
  8. Implied Volatility Surging for Biohaven Pharmaceutical (BHVN) Stock Options
  9. Here's Why Biohaven Pharmaceutical Jumped 20% Today
  10. CBX: Strong earnings for financials a good start
  11. General Electric, Biohaven Pharmaceutical Holding, Tesla and More Are Trending
  12. Biohaven Broadens Senior Leadership Team With Veteran Pharma Commercial Experience
  13. Biohaven Enrolls First Patient in Phase 2/3 Trial of BHV-3500, Third-Generation CGRP Receptor Antagonist, for the Acute Treatment of Migraine
  14. Biohaven Secures Priority Review Voucher (PRV) To Expedite Regulatory Review Of Rimegepant Zydis ODT New Drug Application
  15. Biohaven Pharmaceutical Holding Co Ltd (BHVN) CEO Vlad Coric Sold $5 million of Shares
  16. Has Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Got Enough Cash?
  17. Biohaven Enrolls First Patient In Phase 3 Spinocerebellar Ataxia Clinical Trial Of Troriluzole
  18. Biohaven Announces Completion of Pre-NDA Meeting With FDA for Oral CGRP Receptor Antagonist Rimegepant
  19. Factors of Influence in 2019, Key Indicators and Opportunity within Expedia Group, Lumentum, Patterson Companies, Allscripts Healthcare Solutions, AtriCure, and Biohaven Pharmaceutical Holding — New Research Emphasizes Economic Growth
  20. Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial And Recent Business Results